A Pharmacokinetic Model of a Tissue Implantable Insulin Sensor

While implantable sensors such as the continuous glucose monitoring system have been widely studied, both experimentally and mathematically, relatively little attention has been applied to the potential of insulin sensors. Such sensors can provide feedback control for insulin infusion systems and pu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced healthcare materials 2015-01, Vol.4 (1), p.87-97
Hauptverfasser: Bisker, Gili, Iverson, Nicole M., Ahn, Jiyoung, Strano, Michael S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:While implantable sensors such as the continuous glucose monitoring system have been widely studied, both experimentally and mathematically, relatively little attention has been applied to the potential of insulin sensors. Such sensors can provide feedback control for insulin infusion systems and pumps and provide platforms for the monitoring of other biomarkers in vivo. In this work, the first pharmacokinetic model of an affinity sensor is developed for insulin operating subcutaneously in the limit of where mass transfer across biological membranes reaches a steady state. Using a physiological, compartmental model for glucose, insulin, and glucagon metabolism, the maximum sensor response and its delay time relative to plasma insulin concentration, are calculated based on sensor geometry, placement, and insulin binding parameters for a sensor localized within adipose tissue. A design relation is derived linking sensor dynamics to insulin time lag and placement within human tissue. The model should find utility in understanding dynamic insulin responses and forms the basis of model predictive control algorithms that incorporate sensor dynamics. An in vivo insulin affinity sensor is modeled and optimized using a full physiological compartmental model for glucose, insulin, and glucagon metabolism. The detection platform is based on fluorescent sensors encapsulated within a hydrogel implanted subcutaneously enabling external optical detection. The correlation between insulin–sensor interaction parameters and hydrogel dimensions is explicated to the sensor response and time lag relative to plasma concentration, providing theoretical grounds for experimental designs.
ISSN:2192-2640
2192-2659
2192-2659
DOI:10.1002/adhm.201400264